Osimertinib's evolution has marked a major breakthrough in cancer research, especially in the treatment of non-small cell lung carcinoma (non-small cell lung carcinoma).In patients with EGFR mutation-positive non-small cell lung carcinoma, osimertinib, a third generation EGFR TKI (TKI), has demonstrated outstanding effectiveness.The aim of this article is to explore the advancements and challenges in the progression of osimertinib, emphasizing its impact on patient outcomes and the future directions of research.The treatment of EGFR mutation-positive non-small cell lung carcinoma faces a major challenge in the form of osimertinib resistance.This article discusses…
